Quick Answer
Vera Therapeutics, Inc. reported Cash and Equivalents of $354.73 million for fiscal year 2025.
Vera Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $354.73M | +282.9% |
| 2024 | $92.65M | +102.8% |
| 2023 | $45.68M | +5.1% |
| 2022 | $43.46M | -45.5% |
| 2021 | $79.67M | +48.5% |
| 2020 | $53.65M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $57.77M | +112.0% | +17.6% |
| June 30, 2025 | $49.12M | +95.8% | -10.8% |
| March 31, 2025 | $55.09M | -20.3% | -40.5% |
| December 31, 2024 | $92.65M | +102.8% | +239.9% |
| September 30, 2024 | $27.26M | -0.7% | +8.7% |
| June 30, 2024 | $25.09M | -26.0% | -63.7% |
| March 31, 2024 | $69.11M | -49.7% | +51.3% |
| December 31, 2023 | $45.68M | +5.1% | +66.5% |
- Vera Therapeutics, Inc. showed an increase of +282.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Vera Therapeutics, Inc.’s cash and equivalents has grown by 561.1% (from $53.65 million to $354.73 million).
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: